Outcome analysis of CD371^pos vs CD371^neg BCP-ALL. In a total of 1796 patients (158 CD371^pos and 1638 CD371^neg at diagnosis) from the screening and validation cohorts, the 5-year EFS was 88.3% in CD371^pos BCP-ALLs vs 82.4% in CD371^neg BCP-ALLs (P = .07).